ICON, already global clinical development partner to Bristol Myers-Squibb, have added to the agreement by announcing a preferred provider agreement with BMS in early-phase studies, reports inpharm.com.
The agreement includes full service clinical pharmacology and exploratory clinical studies, based in Manchester in the UK and elsewhere around the world. ICON will also be responsible for all the scientific support services during the trials, such as biostatistics and clinical monitoring, amongst a variety of others.
Dr Mario Rocci, president of ICON Development Solutions, is looking forward to “demonstrating the same values and efficiencies to BMS’s early phase clinical programmes” as they do with phase II-IV studies. Under this new agreement, ICON expects to be able to report “significant cost savings and productivity” by putting it’s global network to use.
Looking for a job in the pharmaceutical industry? Start by clicking here, now